Walid Ayoub, MD
Hepatology · West Hollywood, CANPI 1073524211
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $285,704 of the $415,904 with a category attached, or 68.7%. 14 manufacturers reported payments, led by Gilead at 32.9% of the total. 2025 is the largest year on record at $136,245, 5.5 times the $24,739 reported in 2019. Among hepatology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $1168.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$137K
- Intercept Pharmaceuticals, Inc.$92K
- Madrigal Pharmaceuticals$51K
- Ipsen Biopharmaceuticals, Inc$49K
- GSK$37K
- Novo Nordisk$32K
- plus $17K from 8 others
Across 173 payments — averaging $3891.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$190K
- Madrigal Pharmaceuticals$150K
- Gilead$131K
- Ipsen Pharma SAS$56K
- Pfizer$48K
- Intercept Pharma Europe Ltd.$41K
- plus $58K from 2 others
What the payments were for
- Consulting fees$90,72122%
- Speaking & faculty fees$285,70469%
- Travel & lodging$29,4937%
- Food & beverage$9,9862%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 142 | $136,812 |
| Intercept Pharmaceuticals, Inc. | 80 | $92,385 |
| Madrigal Pharmaceuticals | 47 | $51,475 |
| Ipsen Biopharmaceuticals, Inc | 26 | $49,473 |
| GSK | 12 | $36,839 |
| Novo Nordisk | 13 | $31,914 |
| Mirum Pharmaceuticals, Inc. | 17 | $9,901 |
| Perspectum Diagnostics Ltd | 4 | $3,909 |
| Bayer | 2 | $1,525 |
| Eton Pharmaceuticals, Inc. | 1 | $1,000 |
| AbbVie | 8 | $330 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $192 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $118 |
| Calliditas Therapeutics US Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCALIVA$91,543
- Vemlidy$60,252
- REZDIFFRA$50,872
- IQIRVO$45,977
- Epclusa$23,231
- Livdelzi$21,317
- Wegovy$15,965
- Livmarli$9,543
- Stivarga$1,525
- GALZIN$1,000
- CARGLUMIC ACID$1,000
- BETAINE ANHYDROUS$1,000
- NITISINONE$1,000
- LiverMultiScan$394
- Mavyret$125
- XIFAXAN$118
- RESMETIROM$106
How this compares
$415,904 in reported general payments places this provider in the 90th percentile of 36 hepatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 14 | $338,812 |
| VemlidyTenofovir Alafenamide | 148 | $242,360 |
| XifaxanRifaximin | 69 | $242,273 |
| OcalivaObeticholic Acid | 14 | $146,086 |
| Ursodiol | 209 | $38,265 |
| Mycophenolate Mofetil | 27 | $7,687 |
| Entecavir | 53 | $3,748 |
| Azathioprine | 59 | $3,103 |
| Lactulose | 35 | $1,437 |
| Spironolactone | 51 | $540 |
| Propranolol Hcl | 40 | $525 |
| Furosemide | 48 | $220 |
| Prednisone | 32 | $184 |
| Metformin Hcl | 12 | $78 |
| Carvedilol | 21 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $136,812 | $581,172162 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $192 | $242,27369 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $92,385 | $146,08614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 36 hepatology providers in California.
Other hepatology in West Hollywood
- Ju Dong YangWest Hollywood$46K
- Paul MartinWest Hollywood$39K
- Alexander KuoWest Hollywood$7K
- Aarshi VipaniWest Hollywood$1K
- Yun WangWest Hollywood$487
- Robert GishFolsom$1.9M
- Edward MenaPasadena$624K
- Tarek HassaneinCoronado$278K
- Ke-Qin HuOrange$239K
- Vinay SundaramLos Angeles$203K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.